{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:53:28Z","timestamp":1787698408292,"version":"build-2784847793"},"reference-count":45,"publisher":"Georg Thieme Verlag KG","issue":"01","funder":[{"DOI":"10.13039\/501100008750","name":"Shanghai Hospital Development Center","doi-asserted-by":"crossref","award":["SHDC12018X04"],"award-info":[{"award-number":["SHDC12018X04"]}],"id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"crossref","award":["18140901602"],"award-info":[{"award-number":["18140901602"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"crossref","award":["18140901600"],"award-info":[{"award-number":["18140901600"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81770840"],"award-info":[{"award-number":["81770840"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81970716"],"award-info":[{"award-number":["81970716"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81400844"],"award-info":[{"award-number":["81400844"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81800720"],"award-info":[{"award-number":["81800720"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Metab Res"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The short-term effects of long-acting somatostatin analogues (SSAs) on lipid\n                    profiles in patients with acromegaly are not well studied. We retrospectively\n                    analyzed the effects of SSAs on lipid profiles and associated cardiovascular\n                    risk factors in a cohort of 120 newly diagnosed acromegaly patients. In this\n                    study, 69 females and 51 males were included. These patients were treated with\n                    either octreotide LAR (OCT) or lanreotide SR (LAN) for 3 months. After SSAs\n                    treatment, both GH and IGF-1 significantly decreased (p&lt;0.001).\n                    Triglyceride (TG), total to high-density lipoprotein cholesterol (HDL-C) ratio,\n                    and lipoprotein (a) [Lp(a)] levels were significantly decreased, while HDL-C\n                    levels were increased (p&lt;0.05). The reduction of mean serum GH\n                        (GHm) was positively associated with the decrease of TG\n                    (r=0.305, p=0.001) and Lp(a) (r=0.257, p=0.005),\n                    as well as the increase of HDL-C (r=\u22120.355, p&lt;0.001).\n                    The changes of lipid profiles were observed only in OCT group, but not in LAN\n                    group. In addition, systolic blood pressure (SBP) had significantly declined\n                    after SSAs treatment, with an average reduction of 4.4\u2009mmHg\n                    (126.7\u00b11.28 vs. 122.3\u00b11.44\u2009mmHg, p=0.003), while\n                    no change was observed regarding diastolic blood pressure (DBP)\n                    (p&gt;0.05). Fasting insulin, fasting C-peptide, and HOMA-IR were\n                    significantly decreased after SSAs treatment. In conclusion, our current study\n                    revealed that short-term SSAs treatment improves lipid profiles and other\n                    cardiovascular risk factors in patients with acromegaly.<\/jats:p>","DOI":"10.1055\/a-1717-9332","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T23:30:26Z","timestamp":1641425426000},"page":"25-32","source":"Crossref","is-referenced-by-count":9,"title":["Effects of Long-Acting Somatostatin Analogues on Lipid Metabolism in\n                    Patients with Newly Diagnosed Acromegaly: A Retrospective Study of 120\n                        Cases"],"prefix":"10.1055","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0646-5784","authenticated-orcid":false,"given":"Xiao-qing","family":"Shao","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Huashan Hospital, Fudan\n                    University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-yuan","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Huashan Hospital, Fudan University,\n                    Shanghai, China"},{"name":"Shanghai Pituitary Tumor Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Huashan Hospital, Fudan\n                    University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye-ping","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Huashan Hospital, Fudan\n                    University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-fei","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Huashan Hospital, Fudan\n                    University, Shanghai, China"},{"name":"Shanghai Pituitary Tumor Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-juan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Huashan Hospital, Fudan\n                    University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Huashan Hospital, Fudan\n                    University, Shanghai, China"},{"name":"Shanghai Pituitary Tumor Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-fang","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Huashan Hospital, Fudan\n                    University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Huashan Hospital, Fudan\n                    University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-ying","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Huashan Hospital, Fudan\n                    University, Shanghai, China"},{"name":"Shanghai Pituitary Tumor Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-fei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Huashan Hospital, Fudan University,\n                    Shanghai, China"},{"name":"Shanghai Pituitary Tumor Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Huashan Hospital, Fudan University,\n                    Shanghai, China"},{"name":"Shanghai Pituitary Tumor Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Huashan Hospital, Fudan\n                    University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-yun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Huashan Hospital, Fudan\n                    University, Shanghai, China"},{"name":"Shanghai Pituitary Tumor Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"He","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Huashan Hospital, Fudan\n                    University, Shanghai, China"},{"name":"Shanghai Pituitary Tumor Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-ming","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Huashan Hospital, Fudan\n                    University, Shanghai, China"},{"name":"Shanghai Pituitary Tumor Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,1,5]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1210\/er.2009-0033","article-title":"Mortality in patients with pituitary disease","volume":"31","author":"M Sherlock","year":"2010","journal-title":"Endocr Rev"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000438903","article-title":"Cardiovascular disease and sleep-disordered breathing in acromegaly","volume":"103","author":"A S Powlson","year":"2016","journal-title":"Neuroendocrinology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2265.2008.03181.x","article-title":"Amelioration of cardiovascular risk factors with partial biochemical control of\n                    acromegaly","volume":"69","author":"S P Delaroudis","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0021-9150(99)00426-8","article-title":"LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients.\n                    Effects of octreotide therapy. Italian multicenter octreotide study group","volume":"151","author":"M Arosio","year":"2000","journal-title":"Atherosclerosis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1210\/jc.2008-0299","article-title":"Impact of treating acromegaly first with surgery or somatostatin analogs on\n                    cardiomyopathy","volume":"93","author":"A Colao","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1210\/jc.2009-2670","article-title":"A consensus on criteria for cure of acromegaly","volume":"95","author":"A Giustina","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000486001","article-title":"Metabolic complications of acromegaly","volume":"49","author":"M Mercado","year":"2018","journal-title":"Front Horm Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1210\/jc.2009-0941","article-title":"Effects of initial therapy for five years with somatostatin analogs for\n                    acromegaly on growth hormone and insulin-like growth factor-I levels, tumor\n                    shrinkage, and cardiovascular disease: a prospective study","volume":"94","author":"A Colao","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s12020-016-0995-5","article-title":"Effects of long-term combined treatment with somatostatin analogues and\n                    pegvisomant on cardiac structure and performance in acromegaly","volume":"55","author":"R S Auriemma","year":"2017","journal-title":"Endocrine"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s12020-018-1797-8","article-title":"Changes in metabolic parameters and cardiovascular risk factors after\n                    therapeutic control of acromegaly vary with the treatment modality. Data from\n                    the Bic\u00eatre cohort, and review of the literature","volume":"63","author":"C Briet","year":"2019","journal-title":"Endocrine"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/BF03349161","article-title":"Serum leptin levels in acromegalic patients before and during somatostatin\n                    analogs therapy","volume":"26","author":"R Baldelli","year":"2003","journal-title":"J Endocrinol Invest"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1530\/eje.0.1460303","article-title":"Effect of a six-month treatment with lanreotide on cardiovascular risk factors\n                    and arterial intima-media thickness in patients with acromegaly","volume":"146","author":"A Colao","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1210\/jc.2005-2347","article-title":"Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine\n                    years) prospective study of its efficacy in the control of disease activity and\n                    tumor shrinkage","volume":"91","author":"R Cozzi","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1177\/106002809402801014","article-title":"Effect of octreotide on plasma lipid metabolism in acromegaly","volume":"28","author":"P Benito","year":"1994","journal-title":"Ann Pharmacother"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"846","DOI":"10.4158\/EP.14.7.846","article-title":"Effects of lanreotide autogel on growth hormone, insulinlike growth factor 1,\n                    and tumor size in acromegaly: a 1-year prospective multicenter study","volume":"14","author":"R Attanasio","year":"2008","journal-title":"Endocr Pract"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1210\/jc.2012-3072","article-title":"A comprehensive study of clinical, biochemical, radiological, vascular, cardiac,\n                    and sleep parameters in an unselected cohort of patients with acromegaly\n                    undergoing presurgical somatostatin receptor ligand therapy","volume":"98","author":"A K Annamalai","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1046\/j.1365-2265.2003.01849.x","article-title":"Effects of treatment with Sandostatin LAR on small dense LDL and remnant-like\n                    lipoproteins in patients with acromegaly","volume":"59","author":"KC B Tan","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref18","first-page":"3015854","article-title":"Impact of long-acting somatostatin analogues on glucose metabolism in\n                    acromegaly: a hospital-based study","author":"M Shen","year":"2018","journal-title":"Int J Endocrinol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1210\/er.2002-0022","article-title":"Systemic complications of acromegaly: epidemiology, pathogenesis, and\n                    management","volume":"25","author":"A Colao","year":"2004","journal-title":"Endocr Rev"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1210\/jcem.87.4.8364","article-title":"Cardiovascular risk factors in acromegaly before and after normalization of\n                    serum IGF-I levels with the GH antagonist pegvisomant","volume":"87","author":"G Sesmilo","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1210\/jc.2002-021746","article-title":"The effects of depot long-acting somatostatin analog on central aortic pressure\n                    and arterial stiffness in acromegaly","volume":"88","author":"J C Smith","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/cen.12356","article-title":"Three noninvasive methods in the evaluation of subclinical cardiovascular\n                    disease in patients with acromegaly: epicardial fat thickness, aortic stiffness\n                    and serum cell adhesion molecules","volume":"80","author":"O Topaloglu","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1530\/EC-19-0430","article-title":"Persistent inflammation and endothelial dysfunction in patients with treated\n                    acromegaly","volume":"8","author":"TL C Wolters","year":"2019","journal-title":"Endocr Connect"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1210\/jc.2009-2570","article-title":"Cardiovascular risk factors in patients with uncontrolled and long-term\n                    acromegaly: comparison with matched data from the general population and the\n                    effect of disease control","volume":"95","author":"C Berg","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1365-2265.2008.03323.x","article-title":"Alterations in biomarkers of cardiovascular disease (CVD) in active\n                    acromegaly","volume":"70","author":"L Boero","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2265.2012.04414.x","article-title":"GH levels and insulin sensitivity are differently associated with biomarkers of\n                    cardiovascular disease in active acromegaly","volume":"77","author":"L Boero","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1046\/j.1365-2265.2001.01256.x","article-title":"Increased arterial intima-media thickness by B-M mode echodoppler\n                    ultrasonography in acromegaly","volume":"54","author":"A Colao","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4158\/EP.13.4.363","article-title":"Increase of classic and nonclassic cardiovascular risk factors in patients with\n                    acromegaly","volume":"13","author":"L Vilar","year":"2007","journal-title":"Endocr Pract"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1055\/s-0029-1211774","article-title":"Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients:\n                    relation to growth hormone levels and insulin-like growth factor I","volume":"105","author":"J Wildbrett","year":"1997","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11102-007-0067-1","article-title":"Serum markers of cardiovascular risk in patients with acromegaly before and\n                    after six months of treatment with octreotide LAR","volume":"11","author":"B J Potter","year":"2008","journal-title":"Pituitary"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1540-8175.2010.01179.x","article-title":"Evaluation of the impact of treatment on endothelial function and cardiac\n                    performance in acromegaly","volume":"27","author":"E Akgul","year":"2010","journal-title":"Echocardiography"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000371818","article-title":"The metabolic risk in patients newly diagnosed with acromegaly is related to fat\n                    distribution and circulating adipokines and improves after treatment","volume":"103","author":"N C Olarescu","year":"2016","journal-title":"Neuroendocrinology"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s11102-015-0657-2","article-title":"IGF-1 levels across the spectrum of normal to elevated in acromegaly:\n                    relationship to insulin sensitivity, markers of cardiovascular risk and body\n                    composition","volume":"18","author":"T J Reid","year":"2015","journal-title":"Pituitary"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1530\/EJE-12-0753","article-title":"Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum\n                    levels: insights from the Belgian registry of acromegaly","volume":"168","author":"J Verhelst","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1530\/EJE-20-0497","article-title":"Metabolic complications in acromegaly after neurosurgery: a meta-analysis","volume":"183","author":"A Cozzolino","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2018-02281","article-title":"Pegvisomant improves glucose metabolism in acromegaly: a meta-analysis of\n                    prospective interventional studies","volume":"104","author":"T Feola","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1007\/BF03345632","article-title":"Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: a\n                    retrospective, comparative, head-to-head study","volume":"31","author":"R S Auriemma","year":"2008","journal-title":"J Endocrinol Invest"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1210\/jc.2017-02566","article-title":"Somatostatin analogs and glucose metabolism in acromegaly: a meta-analysis of\n                    prospective interventional studies","volume":"103","author":"A Cozzolino","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1210\/jcem.87.7.8573","article-title":"Cardiovascular consequences of early-onset growth hormone excess","volume":"87","author":"A Colao","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1507\/endocrj1954.37.763","article-title":"Nonclassical 3 beta-hydroxysteroid dehydrogenase deficiency in young girls with\n                    hirsutism and premature pubarche","volume":"37","author":"Y Nishi","year":"1990","journal-title":"Endocrinol Jpn"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/cen.12455","article-title":"The beneficial effect of acromegaly control on blood pressure values in\n                    normotensive patients","volume":"81","author":"C Sardella","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ghir.2010.05.003","article-title":"Growth hormone status predicts left ventricular mass in patients after cure of\n                    acromegaly","volume":"20","author":"T L Wexler","year":"2010","journal-title":"Growth Horm IGF Res"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1530\/EJE-12-0753","article-title":"Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum\n                    levels: insights from the Belgian registry of acromegaly","volume":"168","author":"J Verhelst","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1530\/EJE-09-0945","article-title":"Acromegaly per se does not increase the risk for coronary artery disease","volume":"162","author":"H Akutsu","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/BF03344070","article-title":"Improvement of left ventricular hypertrophy and arrhythmias after\n                    lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective\n                    multi-center study","volume":"25","author":"G Lombardi","year":"2002","journal-title":"J Endocrinol Invest"}],"container-title":["Hormone and Metabolic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1717-9332.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T23:31:27Z","timestamp":1641425487000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1717-9332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":45,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2022,1,5]]},"published-print":{"date-parts":[[2022,1]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1717-9332","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0018-5043","1439-4286"],"issn-type":[{"value":"0018-5043","type":"print"},{"value":"1439-4286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}